The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Following comments from a competitor’s CEO that suggest competition for the company’s epilepsy drug is in the works, shares in GW Pharmaceuticals (NASDAQ:GWPH) tumbled by 17.2% in May, according to S&P Global Market Intelligence.
GW Pharmaceuticals has made a name for itself by pioneering research into the use of marijuana-derived cannabinoids as medicine.